Protandim Nrf2 Synergizer has 28 peer-reviewed studies from respected universities all around the world and is NSF and BSCG Certified Drug Free. Get reliable information from PubMed.gov or click the links below.
University of Colorado
Denver Health Medical Center
Children’s Hospital, Denver
Virginia Commonwealth University
Colorado State University
University of Florida
University of Kentucky
University of Michigan
Louisiana State University
Ohio State University
Texas Tech University
National Institute of Aging
Glamorgan University, Wales
Sahlgrenska University Hospital, Sweden
University of Montreal, Quebec Canada
University Hospital, Brno, Czech Republic
Mexican Institute of Social Security, Mexico
VU University Medical Center, Neuroscience Campus
Amsterdam, The Netherlands
"The science behind Protandim Nrf2 Synergizer is different and unique because LifeVantage Corporation doesn't pay for it. In the world of research, this means that the product and its science must be so compelling that Ph.D.s from universities around the world want to study it and want to spend their own time and money doing it. LifeVantage has a product other people are paying to study! That is unheard of, especially in the supplement industry."
Although there are a number of studies referring to Protandim® and Nrf2 activation, the studies referenced here involve direct experimentation involving Protandim®. When available, a direct link to the FULL article is included.
#1 UNIVERSITY OF COLORADO – OXIDATIVE STRESS Full Text
The induction of human superoxide dismutase and catalase in vivo: a fundamentally new approach to antioxidant therapy
Free Radical Biology & Medicine Jan. 2006
Protandim® is not an antioxidant supplement. It is a NRF-2 Activator. This DNA pathway up and down regulates 500 of the 25,000 genes in our body. These genes are called the survival genes. After 120 days, in this human trial, Superoxide Dismutase (SOD) increased by 30 % (+ / - 10%); Catalase increased 54% (+/ - 15%). These indirect antioxidant enzymes neutralize 1,000,000 free radicals per second every second. Oxidative Stress levels were reduced by an average of 40% in 30 days and up to 70% in 120 days - 100% of the time. Oxidative Stress is related to over 250 age-related diseases. The study indicated no evidence of toxicity = Protandim is a safe nutraceutical supplement
#2 UNIVERSITY OF COLORADO - GLUTATHIONE Full Text
Synergistic induction of heme oxygenase-1 by the components of the antioxidant supplement Protandim
Free Radical Biology & Medicine Feb. 2009
Protandim®, up regulates the enzyme Glutathione by 300% in 30 days. Glutathione is the Master Antioxidant in our bodies. It is a powerful Anti-inflammatory agent that crosses the brain barrier & gut barrier (very few things in our bodies can do this). It also detoxifies our liver & kidneys. This study explored whether components of Protandim acted in a synergistic manner in certain cells, specifically if it would induce heme oxygenase. When each component was tested alone, only curcumin showed minimal induction. Together, all five major ingredients in Protandim®,’s patented formula, produced a strong, synergistic induction MUCH greater than the sum of its parts.
#3 LOUISIANA STATE UNIVERSITY – SKIN CANCER Full Text
Protandim, a fundamentally new antioxidant approach in chemoprevention using mouse two-stage skin carcinogenesis as a mode
PLoS One, April 2009
Cancer Study – 100% of the mice were given a Cancer causing agent. Half of the mice were giving Protandim® and the other half NO Protandim®. Protandim® suppressed tumor formation.
1. The half without Protandim® all developed Cancer.
2. The half that received Protandim®
a. 33% developed ZERO Cancer
b. The remaining mice developed 40% Less aggressive Cancer with fewer, smaller tumors
Conclusion: The induction of antioxidant enzymes by Protandim® may be practical for cancer prevention
#4 VIRGINIA COMMONWEALTH UNIVERSITY - Clinical Trial Full Text
Chronic Pulmonary Artery Pressure Elevation Is Insufficient to Explain Right Heart Failure
Circulation, Nov 2009
This study used a lab model of pulmonary hypertension in rats to explore factors contributing to heart failure in animals. Pulmonary hypertension was induced in rats through a drug and by creating an oxygen-poor environment.
• The animals pre-treated with Protandim experienced strong cardio-protective effects.
• Protandim protected the animals’ hearts by increasing the expression of protective genes and preventing the formation of scar tissue.
Protandim® preserved heart functions and demonstrated strong cardio-protective effects in an animal model of lung disease. Osteopontin levels reduced by more than 50%; heart output preserved and cardiac fibrosis (Hardening of the Arteries) was prevented in animals.
Technical version: This study showed that induction of Nrf2 by Protandim® prevents cardiac oxidative stress, preserves HO-1 and VEGF expression and myocardial capillary density, and prevents RV failure without modifying lung angioproliferation. The restoration of Nrf2 and HO-1 signaling can prevent maladaptive RV remodeling and preserve heart (RV) function.
#5 HARVARD UNIVERSITY – MUSCULAR DYSTROPHY Full Text
The Dietary Supplement Protandim Decreases Plasma Osteopontin and Improves Markers of Oxidative Stress in Muscular Dystrophy Mdx Mice
Journal of Dietary Supplements, June 2010
Protandim® IMPROVES markers of Oxidative Stress and Fibrosis in muscular dystrophy mice.
Oxidative damage is thought to be a pertinent factor in the development of Duchenne muscular dystrophy (DMD), the most common and lethal neuromuscular disorder in children. Researchers used surrogate markers and functional measurers in a dystrophin-deficient mouse model of DMD to determine whether Protandim provides any benefit.
After six months on Protandim®, a researchers saw a 48 % average decrease in plasma TBARS (oxidative stress) and a 57 % decrease in plasma osteopontin as well as a 35 % increase in beneficial protective plasma PON1 activity.
o Osteopontin (OPN) is a pleiotropic protein with important roles in inflammation and immunity that has been suggested as a candidate biomarker for disease activity in multiple sclerosis (MS)
o PON1 Paraoxonase: An enzyme associated with high-density lipoprotein (HDL) that is believed to protect against the oxidation of low-density lipoprotein (LDL) and hence to affect the risk of coronary artery disease
#6 LOUISIANA STATE UNIVERSITY – TUMOR SUPPRESSION Full Text
The chemopreventive effects of Protandim: modulation of p53 mitochondrial translocation and apoptosis during skin carcinogenesis
PLoS One, July 2010
The Role of Manganese Superoxide Dismutase (MnSOD) in Skin Cancer – Protandim on Apoptosis
Chemopreventative Effects of Protandim® Examined Further in New Peer-Reviewed Study; Protandim's ability to modulate relationship between superoxide dismutase and tumor suppressor p53 believed responsible for reduction of skin cancers in mice.
MnSOD is a highly inducible protein, and when induced by dietary compounds such as Protandim®, is effective in the suppression of tumor promotion. The results from this study further confirmed and extended our previous findings that Protandim® modulates tumorigenesis via the induction of endogenous antioxidant enzymes. In addition, Protandim® utilizes multiple mechanisms to modulate cell proliferation and apoptosis in vivo and in vitro which both contribute to tumorigenesis. Therefore, these results further demonstrate the effectiveness of multi-modal antioxidant base therapies in chemoprevention. (Excerpt from Discussion)
The induction of MnSOD is gaining interest as an effective novel mechanism of chemoprevention, being that it is the ONLY antioxidant enzyme that when over expressed suppresses tumor formation. MnSOD also has the ability to modulate multiple pathways contributing to skin carcinogenesis.
#7 OHIO STATE UNIVERSITY – CORONARY BYPASS GRAFTS Full Text
Protandim attenuates intimal hyperplasia in human saphenous veins cultured ex vivo via a catalase-dependent pathway.
Free Radical Biology and Medicine, March 2011
PROTANDIM® FOUND TO PREVENT A PROCESS THAT CAUSES BLOOD VESSEL BLOCKAGE.
This study examined the biochemical mechanisms that underlie the ability of Protandim® to suppress intimal hyperplasia-over-proliferation of cells that line the vessel wall, a common adverse event that limits the effectiveness of vascular surgery. Treatment of human saphenous veins with Protandim® blocked intimal hyperplasia and reduced cellular proliferation to that of freshly isolated human saphenous veins.
Protandim® prevents the proliferation of cells that can cause re-blockage of vessels following coronary artery bypass surgery, stinting, and carotid endarterectomy. This will allow patents of Heart Bypass surgery to have a much longer survival rate.
#8 LOUISIANA STATE UNIV. –SKIN CANCER & MnSOD Full Text
The Role of Manganese Superoxide Dismutase in Skin Cancer
Enzyme Research, March 23, 2011
This study used a two-part model to test the effectiveness of Protandim® in chemoprevention. In one approach, researchers applied an SOD mimetic topically to mouse skin. In another approach, Protandim® decreased tumor incidence and multiplicity by 33% and 57 % respectively.
Protandim® may be a novel approach to chemoprevention.
#9 UNIVERSITY OF COLORADO - Nrf2 Therapeutic Potential Full Text
**A MUST read for healthcare professionals**
Oxidative stress in health and disease: The therapeutic potential of Nrf2 activation.
Molecular Aspects of Medicine, August 2011
Nrf2 is referred to as the "master regulator" of the antioxidant response, modulating the expression of hundreds of genes, including not only the familiar antioxidant enzymes, but large numbers of genes that control seemingly disparate processes such as immune and inflammatory responses, tissue remodeling and fibrosis, carcinogenesis and metastasis, and even cognitive dysfunction and addictive behavior. Thus, the dysregulation of Nrf2-regulated genes provides a logical explanation for the connections, both direct and indirect, between observable oxidative stress and perhaps 200 human diseases involving these various physiological processes, each reflecting a network involving many gene products. (Excerpt from Abstract)
This study involved using a Bioassay of the AREc32 cell line to which scientists added solutions containing either Protandim®, sulforaphane, bardoxolone methyl, or dimethyl fumarate. Each of which are known Nrf2 activators. The test was to determine the extent of each item’s ability to activate the Nrf2 pathway leading to gene expression within the cells. The tests were conducted three times. To quote the findings:
• “Luciferase activity is increased up to 100-fold by Protandim® at 30 lg/ml, the most potent Nrf2 activator that we have observed.” (p 237)
• “As seen here, the two important parameters Cmax and FImax are easily observed. The greatest FImax was observed with Protandim at 135-fold” (p 239)
• Among the 10 genes most highly upregulated by Protandim® are a number of notables that encode antioxidant and anti-inflammatory proteins. (p 240)
• “Pathway analysis of results shows significant modulation by Protandim® of pathways involving not only antioxidant enzymes, but of those related to colon cancer, cardiovascular disease, and Alzheimer disease.” ( Abstract)
o Of the 66 Protandim-regulated genes that are associated with Alzheimer disease, only five (SOD1, NQO1, HMOX1, GLRX, and TXN) appear to be in the antioxidant family. Protandim® upregulated ALL five of them… (p 243)
In addition to the discussion of the therapeutic potential of Nrf2 activation for cardiovascular disease, colon cancer, and Alzheimer’s, the study discusses the therapeutic potential as it relates to other diseases such as renal failure, multiple sclerosis, type II diabetes, etc. The study also includes a table indicating the specific genes and by how much Protandim® up or down regulates each gene.
#10 UNIVERSITY OF COLORADO SCHOOL OF MEDICINE – Alcohol abuse and lung injury Full Text
Protandim does not influence alveolar epithelial permeability or intrapulmonary oxidative stress in human subjects with alcohol use disorders
Amer. Journal of Physiology: Lung Cellular and Molecular Physiology, April 2012
Alcohol use disorders (AUDs), including alcohol abuse and dependence, have been linked to the development of acute lung injury (ALI). Prior clinical investigations suggested an association between AUDs and abnormal alveolar epithelial permeability mediated through pulmonary oxidative stress that may partially explain this relationship. We sought to determine if correcting pulmonary oxidative stress in the setting of AUDs would normalize alveolar epithelial permeability in a double-blinded, randomized, placebo-controlled trial of Protandim, a nutraceutical reported to enhance antioxidant activity. We randomized 30 otherwise healthy AUD subjects to receive directly observed inpatient oral therapy with either Protandim (1,350 mg/day) or placebo. Subjects underwent bronchoalveolar lavage (BAL) and blood sampling before study drug administration and after 7 days of therapy……These results suggest that Protandim for 7 days in individuals with AUDs who are newly abstinent does not alter alveolar epithelial permeability. However, our work demonstrates the feasibility of safely conducting clinical trials that include serial bronchoscopies in a vulnerable population at risk for acute lung injury. (Abstract)
#11 COLORADO STATE UNIVERSITY –Phytochemical Activation of Nrf2 Full Text
Phytochemical Activation of Nrf2 Protects Human Coronary
Artery Endothelial Cells against an Oxidative Challenge
Oxidative Medicine and Cellular Longevity, March 2012
Activation of NF-E2-related factor 2 (Nrf2) is a potential therapeutic intervention against endothelial cell oxidative stress and associated vascular disease. The study was done to determine if treatment with Protandim® would induce Nrf2 nuclear localization and phase II antioxidant enzyme protein in human coronary artery endothelial cells (HCAECs), protecting against an oxidant challenge in an Nrf2- dependent manner. The findings indicate:
• Protandim® treatment induced Nrf2 nuclear localization, and HO-1 (778% of control ± 82.25 P < 0.01), SOD1 (125.9% of control ± 6.05 P < 0.01), NQO1 (126% of control ± 6.5 P < 0.01), and GR (119.5% of control ± 7.00 P < 0.05) protein expression in HCAEC (human artery cells).
• Protandim® induces Nrf2 nuclear localization and antioxidant enzyme expression. Protection of Human Coronary Artery Endothelial Cells HCAEC from an oxidative challenge is Nrf2 dependent.
#12 COLORADO STATE UNIVERSITY. – Nrf2 and Cardiomyocyte Protection
Upregulation of phase II enzymes through phytochemical activation of Nrf2 protects cardiomyocytes against oxidant stress
Free Radical Biology and Medicine, March 2013
Oxidative stress has been linked to cardiovascular disease. The purpose of the experiments in this study was to determine if treatment of cardiomyocytes with Protandim® would activates Nrf2, induce phase II detoxification enzymes, and protect cardiomyocytes from oxidant-induced apoptosis in a Nrf2-dependent manner. **They wanted to know if Protandim would protect heart cells from oxidative damage.
• The result – “phytochemical treatment [with Protandim® ] was found to be a more robust activator of Nrf2 than oxidant treatment, supporting the use of the phytochemicals as a potential treatment to increase antioxidant defenses and protect heart cells against an oxidative challenge.
#13 UNIVERSITY OF COLORADO –Acute Mountain Sickness and Nrf2
Nrf2 activation: A potential strategy for the prevention of acute mountain sickness
Free Radical Biology and Medicine, Oct. 2013
Reactive oxygen species (ROS) formed during acute high altitude exposure contribute to cerebral vascular leak and development of acute mountain sickness (AMS). Nuclear factor (erythroid-derived 2)-related factor 2 (Nrf2) is a transcription factor that regulates expression of greater than 90% of antioxidant genes, but prophylactic treatment with Nrf2 activators has not yet been tested as an AMS therapy. We hypothesized that prophylactic activation of the antioxidant genome with Nrf2 activators would attenuate high-altitude-induced ROS formation and cerebral vascular leak and that some drugs currently used to treat AMS symptoms have an additional trait of Nrf2 activation. …….Of nine drugs tested, with the exception of dexamethasone, only drugs that showed the ability to activate Nrf2 (Protandim, methazolamide, nifedipine, amlodipine, ambrisentan, and sitaxentan). Dexamethasone and Protandim were the most powerful in decreasing high-altitude-induced cerebral vascular leak in vivo. (Excerpt from Abstract)
Nrf2 Global™ was established in 2018 and is currently helping lead over 5,000 members and their family's towards an activated lifestyle.
*DISCLAIMER: The views expressed do not necessarily reflect the official policy or position of any agency, organization, employer or company. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease. Individual results may vary. Copyright © 2018-2021 Nrf2 Global™ All Rights Reserved. This website represents unique product experience and may not be duplicated. Furthermore, none of the statements should be construed as dispensing medical advice or making claims regarding the cure of diseases.